Cas:93-07-2 Veratric acid manufacturer & supplier

Chemical Name:Veratric acid

CAS.NO:93-07-2

Synonyms:MFCD00002500;EINECS 202-215-7;Benzoic acid, 3,4-dimethoxy-;3,4-Dimethoxybenzoic acid;Veratric acid

Molecular Formula:C₉H₁₀O₄

Molecular Weight:182.173

HS Code:2918990090

Physical and Chemical Properties:

Melting point:179-182 °C(lit.)

Boiling point:302.9±22.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.533

PSA:55.76000

Exact Mass:182.057907

LogP:1.99

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like MFCD00002500 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Veratric acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid, 3,4-dimethoxy- Use and application,3,4-Dimethoxybenzoic acid technical grade,usp/ep/jp grade.

Related News: The iLet Bionic Pancreas System is a pocket-sized, wearable investigational medical device that is designed to autonomously control blood-sugar levels. Veratric acid manufacturer Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. Veratric acid supplier The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. Veratric acid vendor Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. Veratric acid factory Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.